RaQualia Pharma Inc.

As of June 30, 2026, RaQualia Pharma Inc. carries a market capitalization of 12.31B, placing it among publicly traded companies globally. Its enterprise value stands at 10.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

RaQualia Pharma Inc.'s next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, RaQualia Pharma Inc. has 26.03M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, RaQualia Pharma Inc. maintains a current ratio of 5.78, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 23, 2026, RaQualia Pharma Inc.'s stock has gained approximately 15.37% over the past 52 weeks. The 50-day moving average sits at 579.42, while the 200-day moving average is 708.92.

As of June 30, 2026, RaQualia Pharma Inc. holds 4.70B in cash and equivalents against 2.69B in total debt, resulting in a net debt position of -2.18B. Total book value stands at 7.83B, with working capital of 5.12B providing operational flexibility.